Fig. 6: CA1 theta power during running is reduced by pharmacological activation of CB1Rs expressed in CA1.

a Illustration of the experimental setup. A head-fixed, wild-type mouse is mounted on the wheel. A virtual reality environment is presented on the screen to instigate running, and the virtual position is recorded. Local infusion and neural recordings are achieved using the T-DOpE probe. b Power spectrogram of CP-55,940 infusion session in lower frequency bins (0–20 Hz). The upper panel shows the speed of the mouse. CP-55,940 (mg kg⁻¹; 200 nL; 1 nL s⁻¹) is locally infused at the recording sites after 60 min of baseline. c Representative normalized power spectrum of the baseline (Before infusion; duration: 60 min) and after CP-55,940 infusion (one hour after infusion; duration: 60 min) restricted to running time (>2 cm s⁻¹ and >1 s running epochs). d Representative normalized power spectrum of the baseline (Before infusion; duration: 60 min) and after drug vehicle infusion (one hour after infusion; duration: 60 min) restricted to running time with the same criteria as above. e Comparison of the normalized theta power (6–11 Hz) between baseline and infused vehicle or drug (Paired two-sided t-test, NS: not significant p ≥ 0.05, *p ≤ 0.05 (Baseline vs. Drug Vehicle, p = 0.2737, animal number = 5), (Baseline vs. CP-55,940, p = 0.0026, animal number = 5)). Data are presented as mean ± SD.